Because when Rubenfield signed on board he thought the company would advance MANF, Lympro, Eltoprazine. He never saw that the CEO would switch to ESS. First of all ESS is a dermatolgoy indication what does that have to do with Neurology? Parkinson's, Alzheimer's, etc.
News 
Market Data 
Discover 
